Claritev Corporation
$22.45
▲
3.74%
2026-04-21 06:16:00
www.claritev.com
NYQ: CTEV
Explore Claritev Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$349.35 M
Current Price
$22.45
52W High / Low
$74.07 / $12.04
Stock P/E
—
Book Value
$-10.51
Dividend Yield
—
ROCE
0.97%
ROE
632.6%
Face Value
—
EPS
$-17.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Health Information Services
Employees
3,000
Beta
0.54
Debt / Equity
-26.54
Current Ratio
0.86
Quick Ratio
0.86
Forward P/E
2.37
Price / Sales
0.29
Enterprise Value
$4.88 B
EV / EBITDA
9.12
EV / Revenue
5.06
Rating
None
Target Price
$42.75
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TruBridge, Inc. | $23.18 | 77.96 | $339.43 M | — | 6.05% | 2.52% | $26.74 / $13.88 | $12.25 |
| 2. | Simulations Plus, Inc. | $14.97 | — | $295 M | 0.61% | 5.18% | -41.21% | $36.45 / $11.09 | $6.31 |
| 3. | Zhongchao Inc. | $2.06 | — | $7.52 M | — | -1.4% | -24.88% | $12.18 / $1.44 | $6.39 |
| 4. | GoodRx Holdings, Inc. | $2.37 | 26.67 | $811.9 M | — | 7.56% | 4.54% | $5.81 / $1.77 | $1.81 |
| 5. | Definitive Healthcare Corp. | $1.05 | — | $147.1 M | — | -3.56% | -40.42% | $4.7 / $0.92 | $2.7 |
| 6. | Mangoceuticals, Inc. | $0.51 | — | $7.43 M | — | -62.34% | -1.42% | $2.88 / $0.16 | $1.13 |
| 7. | Privia Health Group, Inc. | $24.08 | 131.66 | $3.02 B | — | 4.27% | 4.03% | $26.51 / $18.77 | $5.96 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 246.55 M | 245.96 M | 241.57 M | 231.33 M | 232.15 M | — |
| Operating Profit | 8.67 M | 10.07 M | 16.58 M | 9.74 M | 13.14 M | — |
| Net Profit | -80.57 M | -69.75 M | -62.64 M | -71.32 M | -137.97 M | — |
| EPS in Rs | -4.75 | -4.11 | -3.69 | -4.2 | -8.13 | -24.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 965.41 M | 930.62 M | 961.52 M | 1.08 B |
| Operating Profit | 45.06 M | 108.26 M | 170.92 M | 334.18 M |
| Net Profit | -284.28 M | -1.65 B | -91.7 M | -572.91 M |
| EPS in Rs | -16.76 | -97 | -5.4 | -33.77 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.89 B | 5.15 B | 6.96 B | 7.37 B |
| Total Liabilities | 5.06 B | 5.07 B | 5.26 B | 5.58 B |
| Equity | -173.9 M | 84.02 M | 1.71 B | 1.79 B |
| Current Assets | 224.37 M | 175.51 M | 193.59 M | 446.74 M |
| Current Liabilities | 261.36 M | 213.79 M | 166.74 M | 175.84 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 117.32 M | 107.62 M | 171.72 M | 372.36 M |
| Investing CF | -121.02 M | -118.12 M | -249.79 M | -104.45 M |
| Financing CF | 2.36 M | -41.31 M | -180.99 M | -115.74 M |
| Free CF | -12.28 M | -10.51 M | 62.87 M | 282.63 M |
| Capex | -129.6 M | -118.12 M | -108.85 M | -89.73 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -3.21% | -10.95% | — | — |
| Earnings Growth % | -1694.86% | 83.99% | — | — |
| Profit Margin % | -176.85% | -9.54% | -53.06% | — |
| Operating Margin % | 11.63% | 17.78% | 30.95% | — |
| Gross Margin % | 67.39% | 69.26% | 81.1% | — |
| EBITDA Margin % | -108.3% | 67.8% | 14.66% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-09-23 | 1:0.025 |